The Norwegian Immunotherapy in Multiple Myeloma Study

Summary

The goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in routine care in Norway. The aim is to close knowledge gaps, generate evidence for future clinical trials and contribute to future consensus on how to monitor for adverse events, and what mitigation strategies should be implemented, so that we can increase patient survival and quality-of-life.

Eligibility

Inclusion criteria

* Participants age ≥ 18 years
* Prior diagnosis of one of the following

  * Multiple myeloma as defined according to IMWG criteria
  * Primary plasma cell leukemia as defined according to IMWG consensus definition
  * AL-amyloidosis as defined according to IMWG criteria
* Planned treatment with one of the following outside clinical trials (list to be amended based on approvals within the EU):

  * Teclistamab (Tecvayli)
  * Elranatamab (Elrexfio)
  * Talquetamab (Talvey)
  * Idecabtagene vicleucel (ide-cel/Abecma)
  * Ciltacabtagene autoleucel (cilta-cel/Carvykti)

Exclusion Criteria:

* None

Conditions4

Interventions5

Related trials

• Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma — Mayo Clinic
• Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function — Washington University School of Medicine
• Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma — Medical College of Wisconsin
• A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) — Genentech, Inc.
• A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant — Pfizer
• Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients — Intergroupe Francophone du Myelome
• Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma — YOUNGIL KOH
• Self-administration of Subcutaneous Elranatamab in the Patients' Homes. — Thomas Lund

Browse More Trials